Moderna To establish New Vaccine Facility In Britain - Moderna (NASDAQ:MRNA)

Moderna Inc MRNA announced an agreement with the United Kingdom government to establish an mRNA Innovation and Technology Center in the U.K.
Additionally, Moderna plans to expand its presence in the U.K. through investments in R&D activities.
Moderna is collaborating with the National Institute for Health Research on a Phase 3 study investigating Moderna's bivalent Omicron-containing booster candidate (mRNA-1273.214) in the U.K.
Moderna expects its manufacturing facility to produce mRNA vaccines, including vaccines against COVID-19, seasonal influenza, respiratory syncytial virus (RSV), and potential other vaccines, with the collaboration of the U.K. government.
Separately, the U.K. government purchased 60 million doses of Moderna's COVID-19 vaccine, which may include authorized booster vaccine candidates for delivery in 2022 and 2023.
CNBC reports that the facility is expected to start producing shots in 2025, and Britain has committed to buy Moderna's vaccines for the next decade under the agreement.
Moderna Chief Executive Stephane Bancel said he aimed for a variant-specific booster to be ready by August, ahead of Britain's planned autumn booster campaign, CNBC added.
Price Action: MRNA shares are down 1.51% at $128.03 during the premarket session on the last check Wednesday.
Photo by mufidpwt via Pixaby